Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor.

Supply of the cancer drug Pluvicto should increase “meaningfully” in the second half of the year, the drug’s manufacturer Novartis said Tuesday amid widespread shortages. Pluvicto, a drug for advanced ...

Phil Low, a Purdue University scholar and entrepreneur who developed cancer therapies and founded seven companies, has died at 78.

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 vipivotide ...

Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week. Novartis, the pharmaceutical company that manufactures Pluvicto, ...

A Novartis sign hangs on the side of an office building in Cambridge, Massachusetts. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free ...

Novartis entered a new era after spinning off Sandoz earlier in October. As the pure-play innovative medicines company reports strong growth from the business it’s now built on, one product faces a ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an earlier ...

New indication authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) expands access to lutetium177 vipivotide tetraxetan in the UK for eligible mCRPC patients earlier in the ...